

Table S1: Formation of the patient cohort.

3161	patients who underwent prostate RT at BWH between 1/09-1/18
867	Pre-RT mpMRI
764	Pre-RT mpMRI at BWH
704	Pre-RT mpMRI at BWH with GE scanner (high-resolution diffusion weighted images (DWI))
497	Pre-RT high B-value (>= 1400) DWI mpMRI with GE scanner
	59 Excluded for the following reasons
	1 1.5T interventional MRI
	10 Hip artifacts
	1 Large hematoma
	4 MRI > 1 month on ADT
	4 MRI > 1 year old
	4 N1 disease
	11 No endorectal coil
	1 Partial prostatectomy
	1 Penile implant
	11 Prior ADT
	1 Prior microwave ablation
	1 Prior sarcoid
	8 Severe DWI artifacts
	1 Wide FOV (pelvis)
438	Final cohort

Table S2: Scanning acquisition parameters. All diffusion-weighted imaging (DWI) scans were obtained with a B-value  $\geq 1000$  s/mm $^2$  with an endorectal coil.

Characteristic	Signa HDxt (N = 237)	DISCOVERY MR750w (N = 201)
Acquisition		
Echo Time	2,500.00 (2,500.00, 2,500.00)	7,550.00 (7,300.00, 7,550.00)
Repetition Time	81.20 (80.60, 81.40)	78.80 (77.90, 79.20)
Field Strength	3.00 (3.00, 3.00)	3.00 (3.00, 3.00)
Image		
Pixel spacing	0.70 (0.70, 0.70)	0.70 (0.70, 0.70)
Slice spacing	3.00 (3.00, 3.00)	4.00 (4.00, 4.00)
Recon Diameter	180.00 (180.00, 180.00)	179.99 (179.99, 179.99)

Table S3: Performance of AI algorithm for segmenting the TZ and PZ.

	TrainPIRADS (N = 150)	TestPIRADS (N = 83)
TZ Dice Median (IQR)	0.88 (0.83, 0.92)	0.89 (0.84, 0.92)
PZ Dice Median (IQR)	0.83 (0.75, 0.88)	0.84 (0.79, 0.87)

Table S4: nnUNet performance.

Performance	TrainPIRADS (N = 150)	TestPIRADS (N = 83)	TestNOPIRADS (N = 205)
Patient-level AUROC	0.906	0.827	0.785
Sensitivity at 0.5 FP	71.8%	72.7%	65.8%
Average Precision	67.8%	67.0%	56.8%

Table S5: Patient-specific volume characteristics.

Patient-level characteristics	TrainPIRADS (N = 150)	TestPIRADS (N = 83)	TestNOPIRADS (N = 205)
Classification			
Num TP	128 (85.33%)	62 (74.70%)	117 (57.07%)
Num FP	5 (3.33%)	9 (10.84%)	36 (17.56%)
Num FN	16 (10.67%)	11 (13.25%)	32 (15.61%)
Num TN	1 (0.67%)	1 (1.20%)	20 (9.76%)
Num Ref DIL			
0	6 (4.00%)	10 (12.05%)	56 (27.32%)
1	97 (64.67%)	49 (59.04%)	118 (57.56%)
2	36 (24.00%)	20 (24.10%)	19 (9.27%)
≥3	11 (7.33%)	4 (4.82%)	12 (5.85%)
Num Test DIL			
0	5 (3.33%)	6 (7.23%)	36 (17.56%)
1	89 (59.33%)	45 (54.22%)	120 (58.54%)
2	44 (29.33%)	25 (30.12%)	41 (20.00%)
≥3	12 (8.00%)	7 (8.43%)	8 (3.90%)
Total Volume (cm <sup>3</sup> )			
Reference	1.84 (0.78, 4.81)	1.31 (0.37, 2.61)	0.28 (0.00, 0.97)
Test	1.50 (0.71, 3.51)	1.02 (0.40, 2.34)	0.52 (0.10, 1.38)

Table S6: Lesion-specific volume characteristics.

Lesion-level characteristics	TrainPIRADS (N = 271)	TestPIRADS (N = 145)	TestNOPIRADS (N = 299)
Classification			
Num TP	145 (53.1%)	73 (50.3%)	129 (43.1%)
Num FP	69 (25.5%)	44 (30.3%)	103 (34.5%)
Num FN	57 (21.0%)	28 (19.3%)	67 (22.4%)
Volume			
All	0.59 (0.20, 1.78)	0.57 (0.23, 1.50)	0.32 (0.11, 0.82)
TP (nonzero)	145; 1.23 (0.58, 3.54)	73; 1.06 (0.47, 1.85)	129; 0.70 (0.32, 1.51)
FP (nonzero)	69; 0.18 (0.08, 0.33)	44; 0.25 (0.09, 0.58)	103; 0.22 (0.10, 0.45)
FN (nonzero)	57; 0.31 (0.19, 0.69)	28; 0.37 (0.21, 0.88)	67; 0.11 (0.07, 0.25)
Contrast			
All	0.77 (0.72, 0.83)	0.78 (0.71, 0.84)	0.77 (0.71, 0.82)
TP (nonzero)	145; 0.73 (0.68, 0.78)	73; 0.72 (0.68, 0.76)	129; 0.73 (0.69, 0.78)
FP (nonzero)	69; 0.84 (0.76, 0.88)	44; 0.83 (0.79, 0.86)	103; 0.81 (0.77, 0.85)
FN (nonzero)	57; 0.82 (0.77, 0.86)	28; 0.81 (0.79, 0.88)	67; 0.78 (0.74, 0.83)
Metrics for TP			
Dice Median (IQR)	145; 0.77 (0.64, 0.84)	73; 0.74 (0.58, 0.82)	129; 0.71 (0.56, 0.79)

Table S7: Detection of clinically significant disease by the AI versus reference contours for subset of cases 303 cases across all 3 cohorts with sextant biopsies.

Location	AI contour AUC	Ref contour AUC	p-value
Left apex	0.71 (0.64, 0.77)	0.74 (0.67, 0.80)	0.24
Right apex	0.73 (0.69, 0.80)	0.76 (0.70, 0.83)	0.29
Left mid	0.70 (0.64, 0.77)	0.70 (0.64, 0.76)	0.81
Right mid	0.77 (0.71, 0.83)	0.78 (0.72, 0.84)	0.75
Left base	0.68 (0.62, 0.74)	0.65 (0.59, 0.71)	0.39
Right base	0.68 (0.62, 0.75)	0.72 (0.65, 0.79)	0.14

Table S8: Lesion-specific characteristics of AI contours for PI-RADS 3-5 lesions.

PI-RADS lesion characteristics	3 (N = 51)	4 (N = 120)	5 (N = 132)
Lesion-Level Metric			
Num TP	21 (41.2%)	82 (68.3%)	115 (87.1%)
Num FN	30 (58.8%)	38 (31.7%)	17 (12.9%)
Performance			
Sensitivity	41.2%	68.3%	87.1%
Volume	0.28 (0.14, 0.65)	0.51 (0.26, 0.81)	2.87 (1.20, 4.84)
Contrast	0.83 (0.78, 0.86)	0.76 (0.71, 0.81)	0.72 (0.67, 0.77)
Metrics for TP			
Dice Median (IQR)	21; 0.47 (0.41, 0.74)	82; 0.74 (0.60, 0.81)	115; 0.78 (0.69, 0.84)

Table S9: Cox regression for factors associated with time to metastasis for the subset of 233 patients with available PI-RADS scores.

CI: confidence interval. HR: hazard ratio. AHR: adjusted hazard ratio. SOC: standard of care treatment. Ref: reference.

Characteristic	HR	p-value	AHR	P-value
Clinical T-stage	-	-		
T1c-T2c (ref)				
T3a-T3b	1.99 [0.43, 9.25]	0.38		
Radiologic T-stage	-	-		
T1-T2 (ref)				
T3a-T3b	2.70 [0.79, 9.25]	0.11		
PIRADS	-	-		
0-4 (ref)				
5	4.00 [0.86, 18.53]	0.08		
Age	0.91 [0.84, 0.99]	0.04	0.94 [0.87, 1.03]	0.018
SOC	0.66 [0.19, 2.27]	0.51		
Year of Treatment	1.05 [0.80, 1.39]	0.72		
MRI model	1.17 [0.26, 5.14]	0.83		
Salvage ADT	9.95 [1.88, 52.65]	0.007	3.85 [0.65, 22.80]	0.14
AI Volume	1.88 [1.17, 3.00]	0.009	1.71 [1.04, 2.80]	0.04

Table S10: Cox regression model for local recurrence.

CI: confidence interval. HR: hazard ratio. AHR: adjusted hazard ratio. SOC: standard of care treatment. Ref: reference. FIR: favorable intermediate-risk. UIR: unfavorable intermediate-risk.

Characteristic	HR	p-value	AHR	p-value
NCCN+	-	-		
Low/FIR (ref)				
UIR/High/Very high	1.85 [0.62, 5.55]	0.27		
Age	0.92 [0.85, 0.99]	0.02	0.92 [0.85, 0.99]	0.02
SOC	0.86 [0.24, 3.08]	0.82		
Year of Treatment	1.07 [0.82, 1.39]	0.64		
MRI model	1.52 [0.49, 4.70]	0.47		
Salvage ADT	4.51 [1.00, 20.38]	0.05	1.73 [0.31, 9.62]	0.53
AI Volume	1.41 [1.00, 1.98]	0.05	1.34 [0.95, 1.89]	0.09

Table S11: Association of AI DIL volume ranges with baseline clinical and radiographic factors

Characteristic	0-0.4 (N = 151)	0.5-1.9 (N = 169)	2.0- (N = 118)	p-value
NCCN+ category				<0.001
Low	58 (38.41%)	45 (26.63%)	4 (3.39%)	
FIR	48 (31.79%)	43 (25.44%)	14 (11.86%)	
UIR	31 (20.53%)	49 (28.99%)	34 (28.81%)	
High	14 (9.27%)	29 (17.16%)	48 (40.68%)	
Very High	0 (0.00%)	3 (1.78%)	18 (15.25%)	
Model				<0.001
Signa HDxt	114 (75.50%)	89 (52.66%)	34 (28.81%)	
DISCOVERY				
MR750w	37 (24.50%)	80 (47.34%)	84 (71.19%)	
PIRADS				<0.001
0-2	9 (5.96%)	6 (3.55%)	1 (0.85%)	
3	16 (10.60%)	6 (3.55%)	1 (0.85%)	
4	15 (9.93%)	47 (27.81%)	10 (8.47%)	
5	10 (6.62%)	35 (20.71%)	77 (65.25%)	
Radiographic T-stage				<0.001
T1	9/50 (18.00%)	6/94 (6.38%)	1/89 (1.12%)	
T2	34/50 (68.00%)	66/94 (70.21%)	32/89 (35.96%)	
T3a	6/50 (12.00%)	20/94 (21.28%)	39/89 (43.82%)	
T3b	1/50 (2.00%)	2/94 (2.13%)	17/89 (19.10%)	




Fig S1: Example of AI (a, c) and reference (b, d) DILs. The green, orange, and red contours correspond to the TZ, PZ, and DIL, respectively. In a), the AI algorithm detected a R TZ-ant PI-RADS 5 lesion, as well as a L apical lesion, which was not present in the reference image (b). However, GS 3+4 disease was present in the L apex on sextant biopsy. In c) the AI algorithm delineated a DIL in the left apex, which was not present in the reference image (d), and could be attributed to an artifact from the endorectal coil.




Fig. S2: Association of volume with expanded NCCN risk category (NCCN+) for a) biochemical failure, b) local failure, and c) metastasis.